Literature DB >> 9396647

Asthma.

R F Lemanske, W W Busse.   

Abstract

For unknown reasons, the morbidity and mortality from asthma are increasing in many parts of the world, making it a global health concern. The heterogeneous nature of the clinical manifestations and therapeutic responses of asthma in both adult and pediatric patients indicate that it may be more of a syndrome rather than a specific disease entity. Numerous factors, including viral infections, allergen and irritant exposure, and exercise, among others, complicate both the short- and long-term management of asthma. Therapeutic intervention has focused on the appreciation that airway obstruction in asthma consists of bronchial smooth muscle spasm and variable degrees of airway inflammation characterized by edema, mucous secretion, and the influx of a variety of inflammatory cells. Choosing appropriate medications depends on the disease severity (intermittent, mild persistent, moderate persistent, severe persistent), patterns of disease activity (exacerbations related to viruses, allergens, exercise, etc), and the age at onset (infancy, childhood, adulthood).

Entities:  

Mesh:

Year:  1997        PMID: 9396647

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  15 in total

Review 1.  Clinical pharmacokinetics of inhaled budesonide.

Authors:  R Donnelly; J P Seale
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Seeking common pathophysiology in asthma, atopy and sinusitis.

Authors:  Paul C Porter; Valentine Ongeri; Amber Luong; Farrah Kheradmand; David B Corry
Journal:  Trends Immunol       Date:  2011-01-14       Impact factor: 16.687

3.  Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma.

Authors:  D M Stafforini; T Numao; A Tsodikov; D Vaitkus; T Fukuda; N Watanabe; N Fueki; T M McIntyre; G A Zimmerman; S Makino; S M Prescott
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

4.  Salbutamol and/or beclomethasone diproprionate in asthma.

Authors:  Sunita Sharma; Preeti Godatwar; L R Kulkarni
Journal:  Indian J Pediatr       Date:  2003-02       Impact factor: 1.967

Review 5.  The Impact of ACE and ACE2 Gene Polymorphisms in Pulmonary Diseases Including COVID-19.

Authors:  Iphigenia Gintoni; Maria Adamopoulou; Christos Yapijakis
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

6.  Myeloid cell HIF-1α regulates asthma airway resistance and eosinophil function.

Authors:  Laura E Crotty Alexander; Kathryn Akong-Moore; Stephanie Feldstein; Per Johansson; Anh Nguyen; Elisa K McEachern; Shari Nicatia; Andrew S Cowburn; Joshua Olson; Jae Youn Cho; Hart Isaacs; Randall S Johnson; David H Broide; Victor Nizet
Journal:  J Mol Med (Berl)       Date:  2012-12-19       Impact factor: 4.599

7.  The effects of nebulized albuterol on esophageal function in asthmatic patients.

Authors:  Brian E Lacy; Carole Mathis; John DesBiens; Mark C Liu
Journal:  Dig Dis Sci       Date:  2008-02-13       Impact factor: 3.199

8.  Targeted IgE Therapy for Patients With Moderate to Severe Asthma.

Authors:  Bradley E Chipps; Patricia L Marshik
Journal:  Biotechnol Healthc       Date:  2004-07

9.  Comprehensive testing of positionally cloned asthma genes in two populations.

Authors:  Craig P Hersh; Benjamin A Raby; Manuel E Soto-Quirós; Amy J Murphy; Lydiana Avila; Jessica Lasky-Su; Jody S Sylvia; Barbara J Klanderman; Christoph Lange; Scott T Weiss; Juan C Celedón
Journal:  Am J Respir Crit Care Med       Date:  2007-08-16       Impact factor: 21.405

Review 10.  Development of atopy and asthma: candidate environmental influences and important periods of exposure.

Authors:  D B Peden
Journal:  Environ Health Perspect       Date:  2000-06       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.